Abstract
Treatment of sepsis has changed little in the past few decades and the lack of improvement is reflected in the relatively steady mortality rate. Much of the initial disappointment surrounding many of the past multicentered clinical trials in sepsis centers on the use of short-term, high-dose steroids. While recent advances focusing on the interplay between inflammation and coagulation are expected to result in important new treatments in sepsis, rekindled enthusiasm for the role of supraphysiologic-dose steroids is adding to the excitement. Specifically, emerging evidence suggests that moderate-dose glucocorticoids may improve outcomes in septic shock patients, in part, by treating occult adrenal insufficiency. One preliminary study that has sparked considerable interest reported a 30% relative reduction in mortality in sepsis patients treated with modest doses of hydrocortisone for 1 week. It appears clear the role of adrenal insufficiency and steroids in septic shock is deserving of a reevaluation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 68-74 |
| Number of pages | 7 |
| Journal | Journal of Intensive Care Medicine |
| Volume | 17 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2002 |
Fingerprint
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine
Cite this
Steroids and sepsis : Time for another reevaluation. / Kenyon, Nicholas; Albertson, Timothy E.
In: Journal of Intensive Care Medicine, Vol. 17, No. 2, 2002, p. 68-74.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Steroids and sepsis
T2 - Time for another reevaluation
AU - Kenyon, Nicholas
AU - Albertson, Timothy E
PY - 2002
Y1 - 2002
N2 - Treatment of sepsis has changed little in the past few decades and the lack of improvement is reflected in the relatively steady mortality rate. Much of the initial disappointment surrounding many of the past multicentered clinical trials in sepsis centers on the use of short-term, high-dose steroids. While recent advances focusing on the interplay between inflammation and coagulation are expected to result in important new treatments in sepsis, rekindled enthusiasm for the role of supraphysiologic-dose steroids is adding to the excitement. Specifically, emerging evidence suggests that moderate-dose glucocorticoids may improve outcomes in septic shock patients, in part, by treating occult adrenal insufficiency. One preliminary study that has sparked considerable interest reported a 30% relative reduction in mortality in sepsis patients treated with modest doses of hydrocortisone for 1 week. It appears clear the role of adrenal insufficiency and steroids in septic shock is deserving of a reevaluation.
AB - Treatment of sepsis has changed little in the past few decades and the lack of improvement is reflected in the relatively steady mortality rate. Much of the initial disappointment surrounding many of the past multicentered clinical trials in sepsis centers on the use of short-term, high-dose steroids. While recent advances focusing on the interplay between inflammation and coagulation are expected to result in important new treatments in sepsis, rekindled enthusiasm for the role of supraphysiologic-dose steroids is adding to the excitement. Specifically, emerging evidence suggests that moderate-dose glucocorticoids may improve outcomes in septic shock patients, in part, by treating occult adrenal insufficiency. One preliminary study that has sparked considerable interest reported a 30% relative reduction in mortality in sepsis patients treated with modest doses of hydrocortisone for 1 week. It appears clear the role of adrenal insufficiency and steroids in septic shock is deserving of a reevaluation.
UR - http://www.scopus.com/inward/record.url?scp=0036175198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036175198&partnerID=8YFLogxK
U2 - 10.1046/j.1525-1489.2002.17202.x
DO - 10.1046/j.1525-1489.2002.17202.x
M3 - Article
AN - SCOPUS:0036175198
VL - 17
SP - 68
EP - 74
JO - Journal of Intensive Care Medicine
JF - Journal of Intensive Care Medicine
SN - 0885-0666
IS - 2
ER -